POLD1

DNA polymerase delta catalytic subunit · P28340 · POLD1 on Sugi Atlas →

2,358 patent compounds predicted against POLD1, 1,754 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Azidothymidine Monophosphate (SCHEMBL13450790)	0.83	1/20
Azidothymidine Monophosphate (SCHEMBL14188505)	0.83	1/20
Azidothymidine Monophosphate (SCHEMBL15094301)	0.83	1/20
SCHEMBL14370679	0.80	1/20
SCHEMBL7193310	0.76	1/20
SCHEMBL13645054	0.76	1/20
SCHEMBL13645185	0.76	1/20
SCHEMBL13645135	0.75	1/20
SCHEMBL13987092	0.75	1/20
Deoxythymidine_Triphosphate (SCHEMBL77831)	0.74	1/20
Deoxythymidine_Triphosphate (SCHEMBL77832)	0.74	1/20
SCHEMBL887724	0.74	1/20
SCHEMBL887725	0.74	1/20
Deoxythymidine_Triphosphate (SCHEMBL1579556)	0.74	1/20
SCHEMBL4370525	0.74	1/20
Deoxythymidine_Triphosphate (SCHEMBL11055949)	0.74	1/20
SCHEMBL13790699	0.74	1/20
SCHEMBL13987091	0.74	1/20
Deoxythymidine_Triphosphate (SCHEMBL14279191)	0.74	1/20
SCHEMBL14378718	0.73	1/20

Clinical trials — most relevant to POLD1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection	PHASE3	UNKNOWN
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)	PHASE3	WITHDRAWN
Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer	PHASE2	COMPLETED
Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer	PHASE2	UNKNOWN
Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors	PHASE2	RECRUITING
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability	PHASE2	ACTIVE_NOT_RECRUITING
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	PHASE2	ACTIVE_NOT_RECRUITING
K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor	PHASE2	UNKNOWN
SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.	PHASE2	NOT_YET_RECRUITING
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis	PHASE2	ACTIVE_NOT_RECRUITING
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers	PHASE1/PHASE2	COMPLETED
Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin	PHASE2	COMPLETED
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)	PHASE2	UNKNOWN
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC	EARLY_PHASE1	RECRUITING
Prevalence of Germline Alterations in Actionable Genes in Endometrial Cancer	nan	NOT_YET_RECRUITING
PErsonalized TReatment for Endometrial Carcinoma	nan	RECRUITING
REal Word aPpLicAtion of Molecular Based Endometrial Cancer Classification	nan	RECRUITING
Spironolactone and XPB-1 Integrity in the TFIIH Complex	nan	ENROLLING_BY_INVITATION
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Cohort of Tumors With POLE/D1 Mutation	nan	RECRUITING
Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.	nan	UNKNOWN
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease	nan	COMPLETED
Quantitative Assessment of the Etiologies of Megalencephaly Associated With a Detectable Tumor Risk	nan	NOT_YET_RECRUITING
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a POLD1 binder may also engage these)

Protein	Name	Similarity
O54747	—	1.000	O54747 →
P28339	—	1.000	P28339 →
P52431	—	1.000	P52431 →
P97283	—	1.000	P97283 →
Q9LRE6	—	0.995	Q9LRE6 →
P54358	—	0.993	P54358 →
O48901	—	0.990	O48901 →
Q2HRD0	—	0.987	Q2HRD0 →
Q9LVN7	—	0.987	Q9LVN7 →
Q1HVC1	—	0.986	Q1HVC1 →
P46588	—	0.986	P46588 →
Q54N97	—	0.985	Q54N97 →
Q8CGK3	—	0.984	Q8CGK3 →
Q3KSP1	—	0.982	Q3KSP1 →
P30316	—	0.982	P30316 →
P15436	—	0.982	P15436 →
Q924S5	—	0.981	Q924S5 →
P03198	—	0.981	P03198 →
Q767K6	—	0.981	Q767K6 →
Q59HJ6	—	0.981	Q59HJ6 →
B8BDV1	—	0.981	B8BDV1 →
O60231	—	0.981	O60231 →
Q9ZVW2	—	0.980	Q9ZVW2 →
P52367	—	0.980	P52367 →
P90829	—	0.980	P90829 →
Q5RAZ4	—	0.979	Q5RAZ4 →
Q9Z321	—	0.979	Q9Z321 →
O95985	—	0.979	O95985 →
LONP1	Lon protease homolog, mitochondrial	0.979	landscape →
P40694	—	0.979	P40694 →